Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries
- 15 December 2012
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 303 (12) , H1418-H1425
Abstract
Melatonin inhibits nitric oxide (NO)-induced relaxation of coronary arteries. We tested the hypothesis that melatonin increases the phosphorylation of phosphodiesterase 5 (PDE5), which increases the activity of the enzyme and thereby decreases intracellular cGMP accumulation in response to NO and inhibits NO-induced relaxation. Sodium nitroprusside (SNP) and 8-Br-cGMP caused concentration-dependent relaxation of isolated coronary arteries suspended in organ chambers for isometric tension recording. In the presence of melatonin, the concentration-response curve to SNP, but not 8-Br-cGMP, was shifted to the right. The effect of melatonin on SNP-induced relaxation was abolished in the presence of the PDE5 inhibitors zaprinast and sildenafil. Melatonin markedly inhibited the SNP-induced increase in intracellular cGMP in coronary arteries, an effect that was also abolished by zaprinast. Treatment of coronary arteries with melatonin caused a nearly fourfold increase in the phosphorylation of PDE5, which increased the catalytic activity of the enzyme and thereby increased the degradation of cGMP to inactive 5′-GMP. Melatonin-induced PDE5 phosphorylation was markedly attenuated in the presence of the PKG1 inhibitors DT-2 or Rp-8-Br-PET-cGMPS and in those arteries in which PKG1 expression was first downregulated by 24-h incubation with SNP before exposure to melatonin. The selective MT2receptor antagonist 4-phenyl-2-propionamidotetralin completely blocked the stimulatory effect of melatonin on PDE5 phosphorylation as well as the inhibitory effect of melatonin on SNP-induced relaxation and intracellular cGMP. Thus, in coronary arteries, melatonin acts via MT2receptors and PKG1 to increase PDE5 phosphorylation, resulting in decreased cGMP accumulation in response to NO and impaired NO-induced vasorelaxation.Keywords
This publication has 60 references indexed in Scilit:
- Melatonin differentially affects vascular blood flow in humansAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- MT2 Receptors Mediate the Inhibitory Effects of Melatonin on Nitric Oxide-Induced Relaxation of Porcine Isolated Coronary ArteriesThe Journal of Pharmacology and Experimental Therapeutics, 2011
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP ActionPharmacological Reviews, 2010
- Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP‐specific PDE5; an effect mediated by RhoA/PKC‐dependent inhibition of protein phosphatase 1British Journal of Pharmacology, 2008
- Role of cGMP‐dependent protein kinase in development of tolerance to nitroglycerine in porcine coronary arteriesBritish Journal of Pharmacology, 2008
- Inhibition of cGMP-Dependent Protein Kinase by the Cell-Permeable Peptide DT-2 Reveals a Novel Mechanism of VasoregulationMolecular Pharmacology, 2004
- Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptorsBritish Journal of Pharmacology, 2000
- Binding of Transducin to Light-Activated Rhodopsin Prevents Transducin Interaction with the Rod cGMP Phosphodiesterase γ-SubunitBiochemistry, 1997
- Modulation of nitric oxide-dependent relaxation of pig tracheal smooth muscle by inhibitors of guanylyl cyclase and calcium activated potassium channelsLife Sciences, 1995
- Vasorelaxing action of melatonin in rabbit basilar arteryGeneral Pharmacology: The Vascular System, 1989